HAIKOU CITY, China, May 11, 2011 /PRNewswire-Asia-FirstCall/ —
China Pharma Holdings, Inc. (NYSE AMEX:
CPHI) (“China Pharma” or the “Company”), a fully-integrated
specialty pharmaceuticals company in China, today announced
financial results for the quarter ended March 31, 2011.
First Quarter 2011 Highlights
Revenue increased 20% to $18.1 million from $15.1 million in the
first quarter of 2010. Cashflow from operations rose 23% to $1.4
million from $1.1 million in first quarter of 2010. Gross profit
grew 12% to $6.9 million from $6.1 million in the first quarter of
2010. Net income, excluding the impact of change in fair value of
derivative liability, increased 3% to $4.4 million, compared $4.3
million in the first quarter of 2010.
“In the first quarter of 2011 we achieved solid sales growth
primarily due to strong performances by our Digestive Diseases and
Anti-Viro product categories. We continue to face moderate
pricing pressure across several of our product categories during
the quarter, but we expect gross margin and revenue to benefit from
anticipated launches of Candesartan and Rosuvastatin in the
seasonally strong second half of the year,” said Ms. Zhilin Li,
China Pharma’s Chairman and CEO. “In addition to the expected
launch of these two higher margin products later in 2011, we
continue to advance our novel cephalosporin-based combination
antibiotic through Phase II clinical trials. Commercializing
exciting new drugs like this, along with first-to-market generic
medicines, is an important part of our strategy to enhance China
Pharma’s growth and profitability.”
First Quarter 2011 ResultsRevenues for the quarter
ended March 31, 2011 were $18.1 million, up 20% from revenues of
$15.1 million for the quarter ended March 31, 2010, reflecting
higher sales across all of t
‘/>”/>
SOURCE
